<?xml version='1.0' encoding='utf-8'?>
<?xml-stylesheet type="text/xsl" href="/v2/static/oai2.xsl"?>
<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2026-10-12T15:42:40Z</responseDate>
  <request identifier="oai:figshare.com:article/34025592" metadataPrefix="oai_dc" verb="GetRecord">https://api.figshare.com/v2/oai</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:figshare.com:article/34025592</identifier>
        <datestamp>2026-09-29T17:23:41Z</datestamp>
        <setSpec>category_4</setSpec>
        <setSpec>category_7</setSpec>
        <setSpec>category_12</setSpec>
        <setSpec>category_14</setSpec>
        <setSpec>category_16</setSpec>
        <setSpec>category_46</setSpec>
        <setSpec>category_61</setSpec>
        <setSpec>category_62</setSpec>
        <setSpec>category_64</setSpec>
        <setSpec>category_132</setSpec>
        <setSpec>portal_5</setSpec>
        <setSpec>item_type_1</setSpec>
        <setSpec>month_year_09_2026</setSpec>
      </header>
      <metadata>
        <oai_dc:dc xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"  xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
          <dc:title>&lt;p&gt;Differential cytokine protein profile and pathway enrichment in early-stage RCC tissues.&lt;/p&gt;</dc:title>
          <dc:creator>Xu Chen (432759)</dc:creator>
          <dc:creator>Zhuangyao Liao (10320830)</dc:creator>
          <dc:creator>Rochelle Wickramasekara (25138173)</dc:creator>
          <dc:creator>Ying Luo (381053)</dc:creator>
          <dc:creator>Panning Wang (25138176)</dc:creator>
          <dc:creator>Sihao Wang (4577650)</dc:creator>
          <dc:creator>Yunru Chen (4351189)</dc:creator>
          <dc:creator>Hang Zhou (230977)</dc:creator>
          <dc:creator>Shuhong Luo (387711)</dc:creator>
          <dc:creator>Shaopeng Qiu (355114)</dc:creator>
          <dc:creator>Ruo-Pan Huang (303129)</dc:creator>
          <dc:subject>Biochemistry</dc:subject>
          <dc:subject>Medicine</dc:subject>
          <dc:subject>Cell Biology</dc:subject>
          <dc:subject>Molecular Biology</dc:subject>
          <dc:subject>Physiology</dc:subject>
          <dc:subject>Immunology</dc:subject>
          <dc:subject>Developmental Biology</dc:subject>
          <dc:subject>Marine Biology</dc:subject>
          <dc:subject>Cancer</dc:subject>
          <dc:subject>Infectious Diseases</dc:subject>
          <dc:subject>using antibody arrays</dc:subject>
          <dc:subject>remains poorly defined</dc:subject>
          <dc:subject>like receptor pathways</dc:subject>
          <dc:subject>invasive biomarker requiring</dc:subject>
          <dc:subject>common urological malignancy</dc:subject>
          <dc:subject>assessed using gepia</dc:subject>
          <dc:subject>analyzed via david</dc:subject>
          <dc:subject>tumors versus controls</dc:subject>
          <dc:subject>t2 metastatic tumors</dc:subject>
          <dc:subject>stage rcc may</dc:subject>
          <dc:subject>stage rcc patients</dc:subject>
          <dc:subject>urinary erbb3 emerged</dc:subject>
          <dc:subject>several cytokines correlated</dc:subject>
          <dc:subject>stage tumors</dc:subject>
          <dc:subject>rcc patients</dc:subject>
          <dc:subject>several cytokine</dc:subject>
          <dc:subject>selected cytokines</dc:subject>
          <dc:subject>related cytokines</dc:subject>
          <dc:subject>urinary erbb3</dc:subject>
          <dc:subject>tumor tissues</dc:subject>
          <dc:subject>tumor microenvironment</dc:subject>
          <dc:subject>transcriptional expression</dc:subject>
          <dc:subject>timer databases</dc:subject>
          <dc:subject>survival outcomes</dc:subject>
          <dc:subject>stimulating factors</dc:subject>
          <dc:subject>serum levels</dc:subject>
          <dc:subject>related genes</dc:subject>
          <dc:subject>reduced immune</dc:subject>
          <dc:subject>poor survival</dc:subject>
          <dc:subject>meier plotter</dc:subject>
          <dc:subject>inflammatory signals</dc:subject>
          <dc:subject>improved outcomes</dc:subject>
          <dc:subject>immune infiltration</dc:subject>
          <dc:subject>functional enrichment</dc:subject>
          <dc:subject>findings suggest</dc:subject>
          <dc:subject>elevated pro</dc:subject>
          <dc:subject>cytokine signaling</dc:subject>
          <dc:subject>cytokine landscape</dc:subject>
          <dc:subject>candidate non</dc:subject>
          <dc:subject>also reduced</dc:subject>
          <dc:subject>20 sets</dc:subject>
          <dc:subject>174 tumor</dc:subject>
          <dc:description>&lt;p&gt;(A) Hierarchical clustering heatmap of 34 differentially expressed cytokines identified by antibody array analysis of RCC tumor, para-cancerous, and normal kidney tissue samples. Differential expression was determined using limma-based linear modeling with Benjamini–Hochberg false discovery rate (FDR) correction (FDR &lt; 0.05). Each column represents one tissue sample, and each row represents one cytokine. The annotation bar above the heatmap indicates sample group classification (normal, para-cancerous, or tumor). Relative cytokine abundance is represented by color intensity, with red indicating higher expression and green indicating lower expression relative to the normalized signal intensity scale. Clustering analysis was performed using Euclidean distance and average linkage. &lt;b&gt;(B)&lt;/b&gt; KEGG pathway enrichment analysis of the 34 differentially expressed cytokines identified by antibody array profiling. The cytokine set was selected based on statistical significance, fold change, and biological relevance following differential expression analysis. Bars indicate the number of cytokines assigned to each enriched signaling pathway. Pathway enrichment was performed using DAVID based on the set of differentially expressed cytokines identified in panel A. Pathway enrichment was performed using DAVID based on the set of differentially expressed cytokines identified in panel A. Enriched pathways included cytokine–cytokine receptor interaction, TNF signaling, PI3K-Akt signaling, Ras signaling, HIF-1 signaling, and Toll-like receptor signaling pathways.&lt;/p&gt;</dc:description>
          <dc:date>2026-09-29T17:23:34Z</dc:date>
          <dc:type>Image</dc:type>
          <dc:type>Figure</dc:type>
          <dc:identifier>10.1371/journal.pone.0358533.g001</dc:identifier>
          <dc:relation>https://figshare.com/articles/figure/_p_Differential_cytokine_protein_profile_and_pathway_enrichment_in_early-stage_RCC_tissues_p_/34025592</dc:relation>
          <dc:rights>CC BY 4.0</dc:rights>
        </oai_dc:dc>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
